Menu Search
Equities

Cipla Ltd

CIPLA:NSI

Cipla Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)1,465.50
  • Today's Change-4.50 / -0.31%
  • Shares traded1.36m
  • 1 Year change+16.87%
  • Beta0.4572
Data delayed at least 15 minutes, as of Nov 21 2024 10:24 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy4
Outperform14
Hold8
Sell6
Strong Sell1

Share price forecast in INR

The 32 analysts offering 12 month price targets for Cipla Ltd have a median target of 1,660.00, with a high estimate of 1,960.00 and a low estimate of 1,204.00. The median estimate represents a 13.62% increase from the last price of 1,461.00.
High34.2%1,960.00
Med13.6%1,660.00
Low-17.6%1,204.00

Dividends in INR

In 2024, Cipla Ltd reported a dividend of 13.00 INR, which represents a 52.94% increase over last year. The 26 analysts covering the company expect dividends of 10.41 INR for the upcoming fiscal year, a decrease of 19.94%.
Div growth (TTM)52.94%
More ▼

Earnings history & estimates in INR

On Oct 29, 2024, Cipla Ltd reported 2nd quarter 2025 earnings of 16.12 per share. This result exceeded the 14.95 consensus of the 5 analysts covering the company and exceeded last year's 2nd quarter results by 15.14%.
The next earnings announcement is expected on Jan 23, 2025.
Average growth rate+5.42%
Cipla Ltd reported annual 2024 earnings of 53.42 per share on May 10, 2024.
Average growth rate+30.70%
More ▼

Revenue history & estimates in INR

Cipla Limited had 2nd quarter 2025 revenues of 70.51bn. This missed the 70.62bn consensus estimate of the 18 analysts following the company. This was 11.41% above the prior year's 2nd quarter results.
Average growth rate+1.54%
Cipla Limited had revenues for the full year 2024 of 257.74bn. This was 13.28% above the prior year's results.
Average growth rate+10.80%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.